Nu Skin Enterprises Coverage Initiated by Analysts at Pivotal Research (NUS)

  |   21 October, 2014   |   330   |   3980

Equities researchers at Pivotal Research began coverage on shares of Nu Skin Enterprises (NYSE:NUS) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $75.00 price target on the stock. Pivotal Research’s target price would indicate a potential upside of 72.02% from the stock’s previous close.



The analysts wrote, “Nu Skin Enterprises is a Global Multi-Level Marketer (MLM) of skin care, nutritional supplements, and weight loss products. After five years of 20% CAGR in sales and 42% CAGR in EPS, Nu Skin hit turbulence in 2014 with a relatively short-lived three month regulatory investigation in China. While this has been successfully resolved, it created a stall in the Chinese business, and a huge negative comp for the 2nd half of 2014. We see EPS down 50% in the 2H and down 31% for the year. That’s the bad news. The good news is that this is a short-term setback, not a long-term problem, in our view. We see 18% EPS growth in 2015 and a return to the historic growth trajectory. The core business is solid and China should return to significant growth. China remains the fastest growing MLM market in the world.”